“…Study designs included randomized controlled trials (n=17; eight crossover and nine parallel), non-randomized interventional studies (n=15), and observational studies (n=18; cohort and before/after designs). Innovator drugs studied included Neoral (cyclosporine; n=32 studies,31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 28 in kidney transplants, three in heart transplants, and one in liver transplants), Prograf (tacrolimus; n=12 studies,63 64 65 66 67 68 69 70 71 72 73 74 seven in kidney transplants, one in heart transplants, one in liver transplants, and three in a mixture of liver, kidney, or heart transplants), and Cellcept (mycophenolate mofetil; n=6 studies,75 76 77 78 79 80 five in kidney transplants and one in liver transplants). Neoral was compared with 12 different generics (Iminoral, Equoral, Gengraf, Cysporin, Zinograf-ME, Neoplanta, Consupren, SangCya (Sang-35), Sigmasporin Microral, Pliva, Cicloral, and Arpimune); Prograf was compared with four different generics (Tacni, Tacrobell, Adoport, and Sandoz-tacrolimus); and Cellcept was compared with five different generics (Myfenax, Medis, Linfonex, Mycept, and Myconol).…”